Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence

ABSTRACT Introduction: Overactive bladder and urge urinary incontinence affect millions of women and men and results in billions of dollars in health-care expenses. First- and second-line therapy includes behavioral modifications and/or pharmacotherapies however, many patients’ symptoms remain or progress on these treatments. There has been concern regarding the detrimental side effects of the most widely prescribed medications for these bladder symptom management. Areas covered: As a result, there has been increased interest in continuous sacral neuromodulation, an FDA approved therapy for refractory urinary urgency and urge urinary incontinence. In this article, we specifically review current research on the efficacy and patient/provider satisfaction and safety profile of the Axonics® System. In addition, we address the current state of sacral neuromodulation and potential future direction and applicability. Expert opinion: The Axonics® system is a safe effective device for the treatment of overactive bladder and urinary urge incontinence. Additionally, it affords patient’s the convenience of a rechargeable, compact, MRI safe system. It should be noted that the rechargeable system, while allowing for approximately 15 years of battery and lead life, may have its challenges in terms of charge burden. Furthermore, this system is easily adapted for experienced implanters of sacral neuromodulating devices.

[1]  B. Blok,et al.  Two‐year outcomes of the ARTISAN‐SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system , 2021, Neurourology and urodynamics.

[2]  B. Blok,et al.  One‐year outcomes of the ARTISAN‐SNM study with the Axonics System for the treatment of urinary urgency incontinence , 2020, Neurourology and urodynamics.

[3]  J. Hippisley-Cox,et al.  Anticholinergic Drug Exposure and the Risk of Dementia , 2019, JAMA internal medicine.

[4]  B. Blok,et al.  A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12‐month results from the RELAX‐OAB study , 2019, Neurourology and urodynamics.

[5]  H. Goldman,et al.  Can Lumbosacral Magnetic Resonance Imaging be Performed Safely in Patients with a Sacral Neuromodulation Device? An In Vivo Prospective Study , 2018, The Journal of urology.

[6]  D. Myers,et al.  Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. , 2018, European urology.

[7]  K. Matzel,et al.  International Continence Society best practice statement for use of sacral neuromodulation , 2018, Neurourology and urodynamics.

[8]  D. Elterman,et al.  The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience , 2018, Neurourology and urodynamics.

[9]  C. Comiter,et al.  Five‐Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation , 2018, The Journal of urology.

[10]  F. Burkhard,et al.  EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. , 2018, European urology.

[11]  H. Goldman,et al.  Removal of Sacral Nerve Stimulation Devices for Magnetic Resonance Imaging: What Happens Next? , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[12]  M. D. Mason,et al.  Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success. , 2016, The Journal of urology.

[13]  M. Barber,et al.  Erratum to: An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP) , 2016, International Urogynecology Journal.

[14]  M. Barber,et al.  An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP) , 2016, International Urogynecology Journal.

[15]  M. McPheeters,et al.  Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis , 2015, Obstetrics and gynecology.

[16]  M. Faraday,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. , 2015, The Journal of urology.

[17]  Stephanie A. Jacobs,et al.  Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet , 2014, Neurourology and urodynamics.

[18]  Y. Reinberg,et al.  Sacral neuromodulation for the dysfunctional elimination syndrome: a 10-year single-center experience with 105 consecutive children. , 2013, Urology.

[19]  C. Thompson,et al.  The impact of OAB on physical activity in the United States: results from OAB-POLL. , 2013, Urology.

[20]  C. Thompson,et al.  The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB‐POLL , 2013, Neurourology and urodynamics.

[21]  K. Coyne,et al.  Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. , 2012, Urology.

[22]  K. Coyne,et al.  Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. , 2012, Urology.

[23]  B. Blok,et al.  Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. , 2011, The Journal of urology.

[24]  T. Griebling Sacral nerve stimulation in the elderly , 2010, International Urogynecology Journal.

[25]  J. Benner,et al.  Patient‐reported reasons for discontinuing overactive bladder medication , 2010, BJU international.

[26]  S. Wexner,et al.  Infection Rates in a Large Investigational Trial of Sacral Nerve Stimulation for Fecal Incontinence , 2010, Journal of Gastrointestinal Surgery.

[27]  Jim C Hu,et al.  Economic costs of overactive bladder in the United States. , 2010, Urology.

[28]  A. Stenzl,et al.  Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury , 2010, Annals of neurology.

[29]  Jennifer M Wu,et al.  Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review , 2010, Neurourology and urodynamics.

[30]  Jim C Hu,et al.  Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community‐based sample , 2009, BJU international.

[31]  F. Klein,et al.  Sacral nerve stimulation for refractory overactive bladder in the elderly population. , 2009, The Journal of urology.

[32]  F. Klein,et al.  Incidence and predictors of complications with sacral neuromodulation. , 2008, Urology.

[33]  M. Spinelli,et al.  Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. , 2008, European urology.

[34]  M. Elhilali,et al.  Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. , 2007, The Journal of urology.

[35]  R. Dmochowski,et al.  Impact of overactive bladder on women in the United States:results of a national survey , 2007, Current medical research and opinion.

[36]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[37]  Dick J Veltman,et al.  Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators , 2006, BJU international.

[38]  Craig A. Smith,et al.  Preliminary results of sacral neuromodulation in 23 children. , 2006, The Journal of urology.

[39]  J. R. Ruud Bosch,et al.  Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. , 2006, The Journal of urology.

[40]  H. Birnbaum,et al.  Employees With Overactive Bladder: Work Loss Burden , 2005, Journal of occupational and environmental medicine.

[41]  M. Chancellor,et al.  How sacral nerve stimulation neuromodulation works. , 2005, The Urologic clinics of North America.

[42]  M. Fall,et al.  Sacral nerve stimulation for refractory urge symptoms in elderly patients , 2004, Scandinavian journal of urology and nephrology.

[43]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[44]  G. Webster,et al.  Sacral neuromodulation in an older, urge-incontinent population. , 2002, American journal of obstetrics and gynecology.

[45]  R A Janknegt,et al.  Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. , 1999, The Journal of urology.